Literature DB >> 7820476

Reconstructive abdominal operations after laparostomy and multiple repeat laparotomies for severe intra-abdominal infection.

V Scripcariu1, G Carlson, J Bancewicz, M H Irving, N A Scott.   

Abstract

Between 1980 and 1993, 18 patients underwent formal laparotomy after laparostomy and healing of the peritoneal cavity by granulation. The majority (12 patients) were men and the median age was 47 (range 22-67) years. Intraabdominal infection following surgery for Crohn's disease (four patients) and necrotizing pancreatitis (six) was the most common primary condition requiring laparostomy. A total of 23 reconstructive operations were carried out on the 18 patients a median of 6 (range 1-18) months after laparostomy. The indication for surgery was for closure and/or resection of an enteric fistula in 13 patients. The site of the fistula included three gastric, two duodenal, 11 small bowel and seven colonic. A further four patients required operation for closure or refashioning of a stoma. Five patients subsequently required a second laparotomy: two for elective restoration of bowel continuity, two for recurrent fistula and one for an acute abdomen. After reconstructive surgery following laparostomy 16 patients were discharged home alive and well, one requiring home parenteral nutrition for short bowel syndrome. In contrast, the two oldest patients in the series died from multiple organ failure immediately after initial reconstructive surgery. Both had pre-existing medical problems and in neither was there evidence of further intra-abdominal infection after reconstruction.

Entities:  

Mesh:

Year:  1994        PMID: 7820476     DOI: 10.1002/bjs.1800811024

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  9 in total

1.  Tension-free mesh hernia repair: recovery and recurrence after one year.

Authors:  K Rose; D Wright; T Ward; C McCollum
Journal:  Ann R Coll Surg Engl       Date:  1999-09       Impact factor: 1.891

2.  Surgery for post-operative entero-cutaneous fistulas: is bowel resection plus primary anastomosis without stoma a safe option to avoid early recurrence? Report on 20 cases by a single center and systematic review of the literature.

Authors:  A Lauro; R Cirocchi; N Cautero; A Dazzi; D Pironi; F M Di Matteo; A Santoro; S Faenza; L Pironi; A D Pinna
Journal:  G Chir       Date:  2017 Jul-Aug

3.  Successful bridging treatment and healing of enteric fistulae by vacuum-assisted closure (VAC) therapy and targeted drainage in patients with open abdomen.

Authors:  Stefan Stremitzer; Andrea Dal Borgo; Thomas Wild; Peter Goetzinger
Journal:  Int J Colorectal Dis       Date:  2011-01-07       Impact factor: 2.571

4.  Management of enterocutaneous fistulas.

Authors:  Manish Kaushal; Gordon L Carlson
Journal:  Clin Colon Rectal Surg       Date:  2004-05

5.  [Fascial healing and wound failure].

Authors:  V Fackeldey; J Höer; U Klinge
Journal:  Chirurg       Date:  2004-05       Impact factor: 0.955

6.  Continuous reinfusion of succus entericus associated with fistuloclysis in the management of a complex jejunal fistula on the abdominal wall.

Authors:  Adriano M Pflug; Edivaldo M Utiyama; Belchor Fontes; Mario Faro; Samir Rasslan
Journal:  Int J Surg Case Rep       Date:  2013-05-23

7.  Outcome of intestinal failure after bariatric surgery: experience from a national UK referral centre.

Authors:  P J Allan; P Stevens; A Abraham; P Paine; K Farrer; A Teubner; G Carlson; S Lal
Journal:  Eur J Clin Nutr       Date:  2016-04-27       Impact factor: 4.016

8.  Small bowel enterocutaneous fistulae: the merits of early surgery.

Authors:  Manoj Gupta; Pankaj Sonar; Rahul Kakodkar; Vinay Kumaran; Ravi Mohanka; Aravinder Soin; Samirn Nundy
Journal:  Indian J Surg       Date:  2008-12-23       Impact factor: 0.656

9.  Treatment strategies in 135 consecutive patients with enterocutaneous fistulas.

Authors:  Ruben G J Visschers; Steven W M Olde Damink; Bjorn Winkens; Peter B Soeters; Wim G van Gemert
Journal:  World J Surg       Date:  2008-03       Impact factor: 3.352

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.